Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab

Autor:	William J. Sasiela, Uwe Schwahn, Francine Petrides, Dirk J. Blom, Maxime Passard, Aurélie Thedrez, Gilles Lambert, Kerry-Anne Rye, Viktoria Gusarova, A. David Marais, Mathias Chatelais
Rok vydání:	2014
Předmět:	medicine.medical_specialty medicine.drug_class Familial hypercholesterolemia Monoclonal antibody Antibodies Monoclonal Humanized Hyperlipoproteinemia Type II Internal medicine medicine Humans Lovastatin Receptor Cells Cultured Alirocumab business.industry PCSK9 fungi Homozygote Serine Endopeptidases Antibodies Monoclonal Fibroblasts medicine.disease Proprotein convertase Flow Cytometry Endocrinology Receptors LDL LDL receptor Kexin lipids (amino acids peptides and proteins) Proprotein Convertases Hydroxymethylglutaryl-CoA Reductase Inhibitors Proprotein Convertase 9 business Cardiology and Cardiovascular Medicine
Zdroj:	Journal of the American College of Cardiology. 64(21):2299-2300
ISSN:	0735-1097
DOI:	10.1016/j.jacc.2014.07.995
Popis:	Proprotein convertase subtilisin kexin type-9 (PCSK9) inhibition using monoclonal antibodies (mAbs) lowers low-density lipoprotein cholesterol (LDL-C) by >50% in heterozygous familial hypercholesterolemia (HeFH) and non-FH dyslipidemic individuals [(1)][1]. Because PCSK9 is a circulating inhibitor
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5a4ddd0aa31c56ca2c674ae55fbb24 Zobrazit plný text záznamu